MediciNova Announces That The National Institutes Of Health Neurological Disorders And Stroke Has Awarded $22M For An Intermediate Size Expanded Access Protocol To Evaluate The Efficacy Of MN-166 In Amyotrophic Lateral Sclerosis
Express News | MediciNova Inc - Nih Awards $22 Million for Eap to Evaluate Mn-166 in ALS
Express News | Medicinova to Support Nih-Funded Expanded Access Clinical Trial to Evaluate Mn166 (Ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
Medicinova and others continue to rank in, with clinical trials starting for ALS (amyotrophic lateral sclerosis) treatments.
Medicinova <4875> has ranked in (as of 10:32). It is significantly up. On the 23rd yesterday, it was announced that the company has received new Expand Access Program research grants from the National Institutes of Health (NIH) in the USA, and has initiated clinical trials targeting ALS patients with MN-166 (Ibudilast) being developed, being considered a buying catalyst. Details are being coordinated with relevant agencies.
Volume change rate ranking (9:00) - Rain, Wind, Sun, Ange's, etc. are ranked.
* In the volume change rate ranking, you can understand the interest of market participants, such as the trend of trading, by comparing the average volume of the recent 5 days with the volume on the delivery day. * Top Volume Change Rate [As of September 20th, 9:32] (Comparison of average volume of the recent 5 days) Stock code Stock name Volume 5-day average volume Volume change rate Stock price change rate <9058> Tracom 542,400 107,185.08 248.86% 0.007
MediciNova: Confirmatory letter.
MediciNova: Interim report
Express News | Reported Earlier, MediciNova's MN-166 (Ibudilast) ALS Clinical Trial Abstract Accepted For Presentation At 2024 NEALS Annual Meeting
Three points to watch in the afternoon session ~ due to the decline in US stocks and the strengthening of the yen, the decline temporarily exceeded 1,500 yen.
In the afternoon trading on the 4th, the following three points should be noted: - The Nikkei average fell sharply, with the decline temporarily exceeding 1500 yen due to the decline in US stocks and the appreciation of the yen. - The dollar-yen rate slowed its decline, and there were also buybacks due to the feeling of being reasonably priced. - Tokyo Electron (<8035>) was the top contributor to the rise in value, with Advantest (<6857>) coming in second. The Nikkei average fell sharply due to the decline in US stocks and the appreciation of the yen, with a decrease of 1280.72 yen (3.31%) compared to the previous day, to 37,405.
Top volume change rate ranking (9:00 am) - NOSAI, Fujisoft, etc. have made the list.
In the volume change rate ranking, you can understand the market participants' interests, such as the trend of speculation, by comparing the average volume of the past 5 days with the volume on the delivery day. ■ Volume Change Rate Top [Current as of September 4, 9:32] (Comparison with average volume of the past 5 days) Stock Code Stock Name Volume 5-day average volume Volume change rate Stock price change rate <7063> Birdman 608,500 107,185.08 209.81% 0.1264
Express News | Medicinova Announces Acceptance of Abstract Regarding Mn-166 (Ibudilast) in Combat-ALS Clinical Trial for Presentation at the 2024 Annual Neals (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
Sector Update: Health Care Stocks Rise Late Afternoon
Sector Update: Health Care Stocks Softer in Afternoon Trading
Sector Update: Health Care
MediciNova Shares Rise as Post-COVID Drug Due to Receive US Patent
MediciNova Gains After Patent Win for Long COVID Therapy
Reported Earlier, MediciNova Receives U.S. Patent Allowance For MN-166, Ensuring Broad Protection For Post-COVID Treatment Through 2042
Three points to watch in the afternoon session ~ rebound but temporary halt at the 75-day moving average.
In the afternoon of the 30th, the following 3 points are worth noting in the trading: - The Nikkei Average rebounded, but paused at the 75-day moving average - The dollar-yen is firm, hovering around 144 yen - The top contributors to the price increase are Advantest <6857> and Softbank Group <9984>. The Nikkei Average rebounded, but paused at the 75-day moving average. It rebounded with an increase of 222.90 yen (+0.58%) to 38,585.43 yen (with a trading volume of approximately 710 million shares) at the end of the morning session.
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Stocks that hit the daily limit up or down in the morning session.
■Stock limit up: Koatsu Kogyo (4059), Magmag (4316), Beemap (4584), KidsWell Bio (4875), Medicinova (5025), Mercury Realtech Innovator (5242), Eyes■Stock limit down *Includes temporary stock limit up and down (indicative value)